<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952091</url>
  </required_header>
  <id_info>
    <org_study_id>TJ202001MMY301</org_study_id>
    <nct_id>NCT03952091</nct_id>
  </id_info>
  <brief_title>TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 3, Randomized, Open-label, Parallel-controlled, Multi-center Study Comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Who Received at Least 1 Prior Line of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma HongKong Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma HongKong Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202,
      Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed
      or refractory multiple myeloma who received at least 1 prior line of treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>18.4 months(Active) 30.7 months(experimental)</time_frame>
    <description>defined as the duration from the date of randomization to either PD, according to the IMWG criteria, or death, whichever occurs first</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">291</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>TJ202, Lenalidomide and Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomide and Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ202, Lenalidomide and Dexamethasone</intervention_name>
    <description>One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.</description>
    <arm_group_label>TJ202, Lenalidomide and Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide and Dexamethasone</intervention_name>
    <description>Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.</description>
    <arm_group_label>Lenalidomide and Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18, male or female;

          2. Subjects must have had documented MM;

          3. At the screening phase, subject must have one or more measurable disease;

          4. Subjects must have received at least 1 prior line treatment* for relapsed or refractor
             MM;

          5. Subjects who are in a state of progressive disease (PD);

          6. Subjects must have life expectancy of no less than 6 months;

          7. Subjects must have an ECOG (Eastern Cooperative Oncology Group) performance status
             score of 0~2;

          8. A woman of child-bearing potential must have a negative serum pregnancy test within 14
             days prior to the first study agent administration, and a negative urine pregnancy
             test on the day of the first study agent administration; as well as those should avoid
             sexual intercourse with the opposite sex or should adopt two reliable methods of
             contraception at the same time during the study period. A woman of child-bearing
             potential is required to take effective contraceptive measures throughout this study
             and within 6 months after the last dosing; female subjects must agree not to donate
             any eggs for the purpose of assisted reproduction throughout this study and within 6
             months after completion of this study;

          9. Male subjects who are sexually active with women of child-bearing potential and have
             not undergone vasoligation must agree to use barrier methods of birth control, or that
             their partners use block caps (cervical cap or dome cap), spermicidal foam,
             contraceptive gel, contraceptive diaphragm, contraceptive cream, or suppository, and
             all male subjects are not allowed to donate sperms throughout this study and within 6
             months after the last dosing;

         10. Subject must sign an informed consent form (ICF) indicating that he or she understands
             the purpose of, and procedures required for, the study and is willing to participate
             in the study;

         11. Subject must be willing and able to adhere to the prohibitions and restrictions
             specified in this protocol.

        Exclusion Criteria:

          1. Subject has received anti-CD38 monoclonal antibody treatment previously;

          2. Subject has received CAR-T cell therapy previously;

          3. Subject has previously received allogenic stem cell transplant, or subject has
             received autologous stem cell transplant within 3 months before administration of the
             study agent;

          4. Primary refractory multiple myeloma;

          5. Subject's disease shows evidence of resistance to lenalidomide;

          6. Subject's disease shows evidence of intolerance to lenalidomide;

          7. Subject is exhibiting clinical signs of central nervous system (CNS) involvement of
             MM;

          8. Subjects with known moderate or severe persistent asthma within the past 5 years;

          9. Subject has active hepatitis B or C virus infection15. Subject is seropositive for
             human immunodeficiency virus (HIV);

         10. Subject has clinically significant cardiac disease;

         11. Subject has known allergies, hypersensitivity, or intolerance to lenalidomide,
             corticosteroids, monoclonal antibodies or human proteins, or their excipients or known
             sensitivity to mammalian-derived products;

         12. Subject with known or suspicious conditions that would lead to failure to abide by the
             study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Wu, Master</last_name>
    <phone>021-60578032</phone>
    <email>stefny.wu@i-mabbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Capital Medical University (CMU) - Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenming Chen, Doctor</last_name>
      <email>xybxx@ccmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Liu, Master</last_name>
      <phone>+8601068964010</phone>
      <phone_ext>2002</phone_ext>
      <email>seek_su9732@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capital Medical University (CMU) - Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhongxia Huang, Master</last_name>
      <email>zhongxia_huang_proxy@parexel.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical college</name>
      <address>
        <city>Bengbu</city>
        <state>Bengbu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fangbing Zhu, Master</last_name>
      <phone>0552-3086021</phone>
      <email>13505520205@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <state>Changchun</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sujun Gao, Doctor</last_name>
      <phone>+86 431 88786015</phone>
      <email>sujung1963@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Hunan</city>
        <state>Changsha</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Zhou, Postdoctor</last_name>
      <phone>86(0)731-88651269</phone>
      <email>zhouhui9403@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fujian</city>
        <state>Fuzhou</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianda Hu, Postdoctor</last_name>
      <phone>+8659183357896</phone>
      <email>drjianda_hu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhongjun Xia, Master</last_name>
      <phone>020-87343392</phone>
      <email>zhongjun_xia_proxy@parexel.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liye Zhong, Doctor</last_name>
      <email>zhong_liye_proxy@parexel.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shunqing Wang, Doctor</last_name>
      <phone>020-81048888</phone>
      <email>shunqing_wang_proxy@parexel.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongqiang Wei, Master</last_name>
      <email>wyq1973@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Zhejiang</city>
        <state>Hangzhou</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhen Cai, Doctor</last_name>
      <email>caiz@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Zhejiang</city>
        <state>Hangzhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Jin, Doctor</last_name>
      <email>jiej0503@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Taiwan</city>
        <state>Kaohsiung</state>
        <zip>833</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Chung Wang, Bachelor</last_name>
      <phone>+886-7-7357-123</phone>
      <phone_ext>3267</phone_ext>
      <email>wang9595@ms32.hinet.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of Kunming medical university</name>
      <address>
        <city>Yunnan</city>
        <state>Kunming</state>
        <zip>650101</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeping Zhou, Doctor</last_name>
      <email>1580837415@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Yunnan Province</name>
      <address>
        <city>Yunnan</city>
        <state>Kunming</state>
        <zip>650221</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tonghua Yang, Master</last_name>
      <email>ynanblood@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Lanzhou</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaming Xi, Doctor</last_name>
      <phone>0931-8356266</phone>
      <email>xiyaming02@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Lanzhou</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pengyun Zeng, Master</last_name>
      <email>zengpengyunlz@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Jiangxi</city>
        <state>Nanchang</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Yu, Doctor</last_name>
      <phone>+86 (0) 791-86297662</phone>
      <email>zengyulii@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Nanjing</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bing Chen, Doctor</last_name>
      <email>chenbing2004@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Nanjing</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijuan Chen, Doctor</last_name>
      <email>chenljb@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical Univ. 1st Hospital</name>
      <address>
        <city>Guangxi</city>
        <state>Nanning</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Luo, Doctor</last_name>
      <email>luojungz@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weijun Fu, Docter</last_name>
      <email>fuwei.jun2010@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University School of Medicine - Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianqing Mi, Doctor</last_name>
      <phone>+390815903382</phone>
      <email>jianqingmi@shsmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunkang Chang, Doctor</last_name>
      <phone>021-64369181</phone>
      <phone_ext>8336</phone_ext>
      <email>changchunkang7010@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Shenyang</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Li, Master</last_name>
      <phone>86-024-83282505</phone>
      <email>liyan2@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Second Hospital</name>
      <address>
        <city>Guangdong</city>
        <state>Shenzhen</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Du, Doctor</last_name>
      <email>duxingz@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Suzhou</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Depei Wu, Doctor</last_name>
      <email>drwudepei@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taiwan</city>
        <state>Taibei</state>
        <zip>100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shang-Yi Huang, Doctor</last_name>
      <phone>+1886-972651059</phone>
      <email>syhuang55@ntuh.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taiwan</city>
        <state>Taichung</state>
        <zip>40705</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chieh-Lin Teng, Master</last_name>
      <phone>+886-423592525</phone>
      <phone_ext>3175</phone_ext>
      <email>drteng@vghtc.gov.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taiwan</city>
        <state>Taipei</state>
        <zip>114</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Shen Dai, Doctor</last_name>
      <phone>+886-2-8792-3311</phone>
      <phone_ext>12623</phone_ext>
      <email>dms1201@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blood disease hospital,Chinese Academy of Medical Science</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gang An, Postdoctor</last_name>
      <phone>+862223909122</phone>
      <email>angang@ihcams.ac.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zonghong Shao, Bachelor</last_name>
      <phone>+86 22 6081 7092</phone>
      <email>shaozonghong@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yafei Wang, Doctor</last_name>
      <email>Drwang2005@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Zhejiang</city>
        <state>Wenzhou</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kang Yu, Doctor</last_name>
      <phone>86-0577-55579486</phone>
      <email>yukang62@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital Of Wuhan</name>
      <address>
        <city>Hubei</city>
        <state>Wuhan</state>
        <zip>430014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongxiang Wang, Doctor</last_name>
      <phone>027-82811080</phone>
      <email>hong'xiang_wang_proxy@parexel.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Henan</city>
        <state>Zhengzhou</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baijun Fang, Doctor</last_name>
      <email>fdation@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po-Shen Ko, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

